Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26522361 | 0.85 | CYP2A6 (0.43) | CYP2A6CA2ACP3ALDH1A1TDP1 | |
| SCHEMBL29720476 | 0.78 | CYP2A6 (0.40) | CYP2A6ACP3ALDH1A1TDP1HPGD | |
| SCHEMBL12401757 | 0.78 | CYP2A6 (0.40) | CYP2A6ACP3ALDH1A1TDP1HPGD | |
| SCHEMBL7831682 | 0.78 | CYP1A2 (0.59) | CYP2A6CA2ALDH1A1TDP1KDM4E | |
| SCHEMBL28423964 | 0.77 | CA2 (0.46) | CYP2A6CA2ALDH1A1TDP1KDM4E | |
| SCHEMBL7831678 | 0.77 | CA2 (0.39) | CA2ALDH1A1TDP1GABRA1GABRB2 | |
| SCHEMBL22967807 | 0.77 | CYP1A2 (0.43) | CYP2A6CA2ALDH1A1TDP1KDM4E | |
| SCHEMBL11955002 | 0.77 | ALDH1A1 (0.48) | CA2ALDH1A1TDP1HTTGABRA1 | |
| SCHEMBL4818310 | 0.74 | KIF11 (0.48) | CYP2A6CA2ACP3ALDH1A1TDP1 | |
| SCHEMBL29972825 | 0.74 | KIF11 (0.48) | CYP2A6CA2ACP3ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP2A6 4169/4885CA2 324/4885ACP3 3604/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CYP2A6 4656/4885CA2 2534/4885ACP3 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.